1. Home
  2. ONMD vs VERU Comparison

ONMD vs VERU Comparison

Compare ONMD & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneMedNet Corp

ONMD

OneMedNet Corp

HOLD

Current Price

$0.70

Market Cap

42.1M

Sector

N/A

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.41

Market Cap

44.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONMD
VERU
Founded
2006
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.1M
44.0M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
ONMD
VERU
Price
$0.70
$2.41
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
165.4K
200.8K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
83.33
N/A
EPS
N/A
N/A
Revenue
$1,359,000.00
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
111.35
N/A
52 Week Low
$0.49
$2.05
52 Week High
$4.22
$7.33

Technical Indicators

Market Signals
Indicator
ONMD
VERU
Relative Strength Index (RSI) 53.00 43.56
Support Level $0.58 $2.12
Resistance Level $0.70 $2.67
Average True Range (ATR) 0.04 0.11
MACD 0.00 -0.03
Stochastic Oscillator 57.87 23.24

Price Performance

Historical Comparison
ONMD
VERU

About ONMD OneMedNet Corp

OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: